deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT06115993

A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Single Ascending Doses and Multiple Doses of AHB-137 in Healthy Participants and HBeAg-negative CHB Patients Receiving Stable Nucleos(t)Ide Analogues (NAs) Treatment

Sponsor: Ausper Biopharma Co., Ltd.

Conditions Hepatitis B, Chronic
Interventions AHB-137 injection Placebo
Updated 8 times since 2023 Last updated: Sep 22, 2025 Started: Aug 3, 2023 Primary completion: Dec 3, 2024 Completion: Jan 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Hepatitis B, Chronic, this trial is ongoing. The trial is conducted by Ausper Biopharma Co., Ltd. and has accumulated 8 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Apr 2024 · 3 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshotRecruiting~Dec 2024 – ~May 2025 · 5 months · monthly snapshotActive Not Recruiting~May 2025 – ~Oct 2025 · 5 months · monthly snapshotActive Not Recruiting~Oct 2025 – present · 9 months · monthly snapshotActive Not Recruiting

Change History

8 versions recorded

  1. Oct 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. May 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Dec 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1 → PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

▶ Show 3 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  2. Jan 2024 — Apr 2024 [monthly]

    Recruiting PHASE1

  3. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

    First recorded

Aug 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ausper Biopharma Co., Ltd.
Data source: Ausper Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations